CSN Login
Members Online: 20

You are here

Lymphoma Patient Survey – Experience with pralatrexate (Folotyn) or belinostat (Beleodaq) for Peripheral T-Cell Lymphoma

Telephone number: 
613-266-8939
Date: 
Saturday, May 19, 2018 - 5:15pm
Image: 
First Name: 
Adam
Last Name: 
Waiser
Announcement removal date: 
Monday, June 11, 2018 - 3:00am
Have you submitted an announcement request to CSN in the past?: 
Yes
Your announcement.: 

Lymphoma Patient Survey – Experience with pralatrexate (Folotyn) or belinostat (Beleodaq) for PTCL

 

If you have or had Peripheral T-Cell Lymphoma (PTCL) and have been treated with pralatrexate (Fotolyn) or belinostat (Beleodaq), you can help by completing our survey.

 

Lymphoma Canada is preparing a submission for the pan¬Canadian Oncology Drug Review (pCODR). The survey provides us with the patient input required for the submission. pCODR uses this information to help them make recommendations to provinces and territories regarding funding for new cancer drugs.

 

You do not need to live in Canada to complete this survey.

 

BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.

 

The survey will be open until midnight Pacific Time on Sunday, June 10, and should only take 10 minutes of your time.

 

You may access the survey by clicking the link below.

 

Peripheral T-Cell Lymphoma Patient Survey – Experience with Folotyn or Beleodaq

 

Please share and help us spread the word.

 

Thank you for your support.

 The above research study announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study.  We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study.  Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider

Check the appropriate category for your announcement: 
Research study, clinical trial, focus group,etc (Requires IRB review and certification. See here for guidelines.)
E-mail: 
adamwaiser@hotmail.com
Contact - Email: 
elizabeth@lymphoma.ca
Contact - First name: 
Elizabeth
Contact - Last name: 
Lye
Subscribe to Comments for "Lymphoma Patient Survey – Experience with pralatrexate (Folotyn) or belinostat (Beleodaq) for Peripheral T-Cell Lymphoma"